{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:12:09Z","timestamp":1787580729591,"version":"build-2736575974"},"reference-count":100,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["ECTZ206376"],"award-info":[{"award-number":["ECTZ206376"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-17-RHUS-0003"],"award-info":[{"award-number":["ANR-17-RHUS-0003"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["847939"],"award-info":[{"award-number":["847939"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["egastro"],"accepted":{"date-parts":[[2023,4,20]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>In spite of the fact that safe and effective vaccines have been available for over 40 years, hepatitis B virus (HBV) remains a major public health problem, as there are 296\u2009million chronically HBV-infected individuals worldwide and 820 000 HBV-related deaths taking place every year. Achieving the goal of HBV cure remains a challenge due to the particularities of the HBV cycle underlying viral persistence. The new understanding of HBV biology and antiviral immune responses has allowed to identify novel drug targets. This has led to a renewed interest in developing new curative strategies and combinations for HBV. In the present review, we aim to summarise the biological and clinical challenges associated with chronic HBV infection. Moreover, we consider the lessons that have been learnt in the past years regarding the preclinical and clinical evaluation of compounds against HBV and how this is driving the field to explore new directions.<\/jats:p>","DOI":"10.1136\/egastro-2023-100021","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T03:26:34Z","timestamp":1698204394000},"page":"e100021","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Opportunities and challenges for hepatitis B cure"],"prefix":"10.1136","volume":"1","clinical-trial-number":[{"clinical-trial-number":"nct04856085","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05276297","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04544956","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05045261","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05630807","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Armando Andres","family":"Roca Suarez","sequence":"first","affiliation":[{"name":"INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, France"},{"name":"University of Lyon, Universit\u00e9 Claude-Bernard (UCBL), Lyon, France"},{"name":"Hepatology Institute of Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-0083","authenticated-orcid":false,"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[{"name":"INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, France"},{"name":"University of Lyon, Universit\u00e9 Claude-Bernard (UCBL), Lyon, France"},{"name":"Hepatology Institute of Lyon, Lyon, France"},{"name":"Department of Hepatology, Croix Rousse hospital, Hospices Civils de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"2025081719115765000_1.2.e100021.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2523562"},{"key":"2025081719115765000_1.2.e100021.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00608-8"},{"key":"2025081719115765000_1.2.e100021.3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","author":"Blach","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025081719115765000_1.2.e100021.4","unstructured":"World Health Organization . Hepatitis B. 2022. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b [Accessed 22 Jan 2023]."},{"key":"2025081719115765000_1.2.e100021.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.013"},{"key":"2025081719115765000_1.2.e100021.6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29479"},{"key":"2025081719115765000_1.2.e100021.7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.018"},{"key":"2025081719115765000_1.2.e100021.8","doi-asserted-by":"crossref","unstructured":"Mak LY , Hui RWH , Fung J , et al . The role of different viral biomarkers on the management of chronic hepatitis B for special issue \u2018challenging issues in the treatment of viral hepatitis\u2019. Clin Mol Hepatol 2023. doi:10.3350\/cmh.2022.0448","DOI":"10.3350\/cmh.2022.0448"},{"key":"2025081719115765000_1.2.e100021.9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2025081719115765000_1.2.e100021.10","doi-asserted-by":"crossref","unstructured":"Wooddell CI , Yuen M-F , Chan H-Y , et al . Rnai-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med 2017;9. doi:10.1126\/scitranslmed.aan0241","DOI":"10.1126\/scitranslmed.aan0241"},{"key":"2025081719115765000_1.2.e100021.11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323153"},{"key":"2025081719115765000_1.2.e100021.12","doi-asserted-by":"crossref","unstructured":"Glebe D , Goldmann N , Lauber C , et al . HBV evolution and genetic variability: impact on prevention, treatment and development of antivirals. Antiviral Res 2021;186. doi:10.1016\/j.antiviral.2020.104973","DOI":"10.1016\/j.antiviral.2020.104973"},{"key":"2025081719115765000_1.2.e100021.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"2025081719115765000_1.2.e100021.14","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jhep.2017.07.011","article-title":"How viral genetic variants and Genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an Individualised approach?","volume":"67","author":"Rajoriya","year":"2017","journal-title":"J Hepatol"},{"key":"2025081719115765000_1.2.e100021.15","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/jvh.13547","article-title":"Hepatitis B virus genome diversity in adolescents: tenofovir disoproxil fumarate treatment effect and HBeAg serocon version","volume":"28","author":"Combet","year":"2021","journal-title":"J Viral Hepat"},{"key":"2025081719115765000_1.2.e100021.16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27254"},{"key":"2025081719115765000_1.2.e100021.17","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00027.2008"},{"key":"2025081719115765000_1.2.e100021.18","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2691"},{"key":"2025081719115765000_1.2.e100021.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00549-4"},{"key":"2025081719115765000_1.2.e100021.20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02844-06"},{"key":"2025081719115765000_1.2.e100021.21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24249"},{"key":"2025081719115765000_1.2.e100021.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.026"},{"key":"2025081719115765000_1.2.e100021.23","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"2025081719115765000_1.2.e100021.24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41426-018-0034-0","article-title":"Use of Elispot assay to study HBs-specific B cell responses in vaccinated and HBV infected humans","volume":"7","author":"Tian","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"2025081719115765000_1.2.e100021.25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121957"},{"key":"2025081719115765000_1.2.e100021.26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jhep.2019.07.015","article-title":"Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B","volume":"72","author":"Le Bert","year":"2020","journal-title":"J Hepatol"},{"key":"2025081719115765000_1.2.e100021.27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jhep.2020.01.024","article-title":"Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV","volume":"73","author":"Vanwolleghem","year":"2020","journal-title":"J Hepatol"},{"key":"2025081719115765000_1.2.e100021.28","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"2025081719115765000_1.2.e100021.29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0167-4889(99)00089-0","article-title":"Evidence for IRF-1-dependent gene expression deficiency in interferon unresponsive Hepg2 cells","volume":"1451","author":"Tnani","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"2025081719115765000_1.2.e100021.30","doi-asserted-by":"publisher","DOI":"10.1081\/DMR-100100564"},{"key":"2025081719115765000_1.2.e100021.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-016-1694-y"},{"key":"2025081719115765000_1.2.e100021.32","doi-asserted-by":"publisher","DOI":"10.1093\/ilar.42.2.89"},{"key":"2025081719115765000_1.2.e100021.33","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3389\/fimmu.2020.00853","article-title":"Diverse virus and host-dependent mechanisms influence the systemic and Intrahepatic immune responses in the woodchuck model of hepatitis B","volume":"11","author":"Michalak","year":"2020","journal-title":"Front Immunol"},{"key":"2025081719115765000_1.2.e100021.34","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021469","article-title":"The chimpanzee model for hepatitis B virus infection","volume":"5","author":"Wieland","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2025081719115765000_1.2.e100021.35","doi-asserted-by":"publisher","DOI":"10.1126\/science.350.6264.1013"},{"key":"2025081719115765000_1.2.e100021.36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/COH.0000000000000616","article-title":"In-vitro and in-vivo models for hepatitis B cure research","volume":"15","author":"Allweiss","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"key":"2025081719115765000_1.2.e100021.37","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.gastro.2018.11.062","article-title":"Challenges, considerations, and principles to guide trials of combination therapies for chronic hepatitis B virus","volume":"156","author":"Anderson","year":"2019","journal-title":"Gastroenterology"},{"key":"2025081719115765000_1.2.e100021.38","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22956"},{"key":"2025081719115765000_1.2.e100021.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.008"},{"key":"2025081719115765000_1.2.e100021.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.003"},{"key":"2025081719115765000_1.2.e100021.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00724-5"},{"key":"2025081719115765000_1.2.e100021.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.003"},{"key":"2025081719115765000_1.2.e100021.43","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01902-09"},{"key":"2025081719115765000_1.2.e100021.44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of Bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (Myr202): a Multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025081719115765000_1.2.e100021.45","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jhep.2022.07.016","article-title":"Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension","volume":"77","author":"Degasperi","year":"2022","journal-title":"J Hepatol"},{"key":"2025081719115765000_1.2.e100021.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.003"},{"key":"2025081719115765000_1.2.e100021.47","unstructured":"Agarwal K , Yuen MF , Wedemeyer H , et al . A phase 1 study evaluating the neutralizing, Vaccinal Monoclonal antibody VIR-3434 in participants with chronic hepatitis B virus infection: preliminary results. International Liver Congress; 2021."},{"key":"2025081719115765000_1.2.e100021.48","unstructured":"Gane E , Jucov A , Dobryanska M , et al . Safety, tolerability, and antiviral activity of the siRNA VIR-2218 in combination with the investigational neutralizing Monoclonal antibody VIR-3434 for the treatment of chronic hepatitis B virus infection: preliminary results from the phase 2 March trial. In: AASLD - The Liver Meeting; 2022."},{"key":"2025081719115765000_1.2.e100021.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00700-z"},{"key":"2025081719115765000_1.2.e100021.50","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV Capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"key":"2025081719115765000_1.2.e100021.51","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","article-title":"Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial","volume":"5","author":"Yuen","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025081719115765000_1.2.e100021.52","doi-asserted-by":"crossref","unstructured":"Feld JJ , Lawitz E , Nguyen T , et al . EDP-514 in healthy subjects and Nucleos(T)Ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B. Antivir Ther 2022;27. doi:10.1177\/13596535221127848","DOI":"10.1177\/13596535221127848"},{"key":"2025081719115765000_1.2.e100021.53","unstructured":"Gane E , Sulkowski M , Ma X , et al . Viral response and safety following discontinuation of treatment with the core inhibitor Vebicorvir and a Nucleos(T)Ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection. In: EASL Digital International Liver Conference; 2021"},{"key":"2025081719115765000_1.2.e100021.54","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328041"},{"key":"2025081719115765000_1.2.e100021.55","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1002\/hep4.2095","article-title":"Safety, pharmacokinetics, and antiviral activity of the Capsid inhibitor AB-506 from phase 1 studies in healthy subjects and those with hepatitis B","volume":"6","author":"Yuen","year":"2022","journal-title":"Hepatol Commun"},{"key":"2025081719115765000_1.2.e100021.56","doi-asserted-by":"crossref","first-page":"S864","DOI":"10.1016\/S0168-8278(22)02024-4","article-title":"Effects of the siRNA JNJ-3989 and\/or the Capsid assembly modulator (CAM-N) JNJ-6379 on viral markers of chronic hepatitis B (CHB): results from the REEF-1 study","volume":"77","author":"Yuen","year":"2022","journal-title":"Journal of Hepatology"},{"key":"2025081719115765000_1.2.e100021.57","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(22)00437-8"},{"key":"2025081719115765000_1.2.e100021.58","unstructured":"Yuen MF . Preliminary 48-week safety and efficacy data of VIR-2218 alone and in combination with pegylated interferon Alfa in participants with chronic HBV infection. AASLD - The Liver Meeting; 2022"},{"key":"2025081719115765000_1.2.e100021.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.023"},{"key":"2025081719115765000_1.2.e100021.60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210027"},{"key":"2025081719115765000_1.2.e100021.61","doi-asserted-by":"crossref","first-page":"S873","DOI":"10.1016\/S0168-8278(22)02041-4","article-title":"Bepirovirsen, Antisense Oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic Immunostimulatory activity via toll-like receptor 8 (Tlr8) Preclinically, correlating with clinical efficacy from the phase 2A study","volume":"77","author":"You","year":"2022","journal-title":"Journal of Hepatology"},{"key":"2025081719115765000_1.2.e100021.62","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon Alfa-2A in patients with chronic HBV infection Na\u00efve to Nucleos(T)Ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"2025081719115765000_1.2.e100021.63","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep4.1633","article-title":"Persistent control of hepatitis B virus and hepatitis Delta virus infection following REP 2139-ca and pegylated interferon therapy in chronic hepatitis B virus\/hepatitis Delta virus Coinfection","volume":"5","author":"Bazinet","year":"2021","journal-title":"Hepatol Commun"},{"key":"2025081719115765000_1.2.e100021.64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/liv.15465","article-title":"A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-Na\u00efve patients with chronic hepatitis B","volume":"43","author":"Yuen","year":"2023","journal-title":"Liver Int"},{"key":"2025081719115765000_1.2.e100021.65","first-page":"S125","article-title":"Liver toxicity in the phase 2 catalyst 206 trial of Inarigivir 400 mg daily added to a nucleoside in HBV Eag negative patients","volume":"73","author":"Agarwal","year":"2020","journal-title":"Journal of Hepatology"},{"key":"2025081719115765000_1.2.e100021.66","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.003"},{"key":"2025081719115765000_1.2.e100021.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.026"},{"key":"2025081719115765000_1.2.e100021.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.12.007"},{"key":"2025081719115765000_1.2.e100021.69","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12942"},{"key":"2025081719115765000_1.2.e100021.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.09.027"},{"key":"2025081719115765000_1.2.e100021.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.028"},{"key":"2025081719115765000_1.2.e100021.72","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S0168-8278(22)00538-4","article-title":"ALT flares were linked to HBsAg reduction, Seroclearance and seroconversion: interim results from a phase IIb study in chronic hepatitis B patients with 24-week treatment of subcutaneous PD-L1 AB Asc22 (Envafolimab) plus Nucleos (T)Ide analogs","volume":"77","author":"Wang","year":"2022","journal-title":"Journal of Hepatology"},{"key":"2025081719115765000_1.2.e100021.73","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1053\/j.gastro.2018.10.032","article-title":"Targeting innate and adaptive immune responses to cure chronic HBV infection","volume":"156","author":"Gehring","year":"2019","journal-title":"Gastroenterology"},{"key":"2025081719115765000_1.2.e100021.74","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.coviro.2021.10.002","article-title":"Immunotherapy and therapeutic vaccines for chronic HBV infection","volume":"51","author":"Lang-Meli","year":"2021","journal-title":"Curr Opin Virol"},{"key":"2025081719115765000_1.2.e100021.75","unstructured":"Barnes E . Phase 1B\/2A study of heterologous Chadox1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose Nivolumab in Virally-suppressed patients with CHB on Nucleos(T)Ide analogues. International Liver Congress; 2022."},{"key":"2025081719115765000_1.2.e100021.76","unstructured":"Swinnen K , Jeng WJ , Romero-Gomez M , et al . Potent and Polyfunctional hepatitis B core (Hbc)\/Surface (Hbs)-Specific Cd8+ and Cd4+ T cell responses observed in adults with chronic hepatitis B (CHB) following targeted Immunotherapy consisting of viral vectors in heterologous prime-boost regimen and Adjuvanted Hbc\/HBs proteins: results on step B cohort of a phase I\/II trial. AASLD - The Liver Meeting; 2022."},{"key":"2025081719115765000_1.2.e100021.77","doi-asserted-by":"crossref","unstructured":"Schmidt S , Mengistu M , Daffis S , et al . Alternating arenavirus vector immunization generates robust polyfunctional genotype cross-reactive HBV-specific Cd8 T cell responses and high anti-HBs titers. J Infect Dis 2023:jiad340. doi:10.1093\/infdis\/jiad340","DOI":"10.1093\/infdis\/jiad340"},{"key":"2025081719115765000_1.2.e100021.78","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.032"},{"key":"2025081719115765000_1.2.e100021.79","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3390\/v14122654","article-title":"Gene editing technologies to target HBV cccDNA","volume":"14","author":"Martinez","year":"2022","journal-title":"Viruses"},{"key":"2025081719115765000_1.2.e100021.80","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1186\/s12879-019-4436-y","article-title":"Inhibition of replication of hepatitis B virus using transcriptional Repressors that target the viral DNA","volume":"19","author":"Bloom","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2025081719115765000_1.2.e100021.81","first-page":"2169","article-title":"Engineered zinc-finger transcription factors inhibit the replication and transcription of HBV in vitro and in vivo","volume":"41","author":"Luo","year":"2018","journal-title":"Int J Mol Med"},{"key":"2025081719115765000_1.2.e100021.82","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/hep4.1933","article-title":"Efficient silencing of hepatitis B virus S gene through CRISPR-mediated base editing","volume":"6","author":"Zhou","year":"2022","journal-title":"Hepatol Commun"},{"key":"2025081719115765000_1.2.e100021.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.12.014"},{"key":"2025081719115765000_1.2.e100021.84","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2023.01.017","article-title":"Eliminating cccDNA to cure hepatitis B virus infection","volume":"78","author":"Zoulim","year":"2023","journal-title":"J Hepatol"},{"key":"2025081719115765000_1.2.e100021.85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02969-8"},{"key":"2025081719115765000_1.2.e100021.86","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.60747","article-title":"Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma","volume":"10","author":"De Crignis","year":"2021","journal-title":"Elife"},{"key":"2025081719115765000_1.2.e100021.87","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canlet.2021.02.024","article-title":"3d human liver Organoids: an in vitro platform to investigate HBV infection, replication and liver tumorigenesis","volume":"506","author":"Rao","year":"2021","journal-title":"Cancer Lett"},{"key":"2025081719115765000_1.2.e100021.88","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jhep.2023.01.019","article-title":"A human liver Organoid screening platform for DILI risk prediction","volume":"78","author":"Zhang","year":"2023","journal-title":"J Hepatol"},{"key":"2025081719115765000_1.2.e100021.89","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-018-9913-7"},{"key":"2025081719115765000_1.2.e100021.90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.022"},{"key":"2025081719115765000_1.2.e100021.91","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.08.034"},{"key":"2025081719115765000_1.2.e100021.92","doi-asserted-by":"crossref","unstructured":"Boettler T , Gill US , Allweiss L , et al . Assessing immunological and virological responses in the liver: implications for the cure of chronic hepatitis B virus infection. JHEP Rep 2022;4. doi:10.1016\/j.jhepr.2022.100480","DOI":"10.1016\/j.jhepr.2022.100480"},{"key":"2025081719115765000_1.2.e100021.93","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158903","article-title":"Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic Cd8+ T cells","volume":"133","author":"Nkongolo","year":"2023","journal-title":"J Clin Invest"},{"key":"2025081719115765000_1.2.e100021.94","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2023.100841","article-title":"Evaluation of the HBV liver reservoir with fine needle aspirates","volume":"5","author":"Testoni","year":"2023","journal-title":"JHEP Rep"},{"key":"2025081719115765000_1.2.e100021.95","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328380"},{"key":"2025081719115765000_1.2.e100021.96","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00649-z"},{"key":"2025081719115765000_1.2.e100021.97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.11.030"},{"key":"2025081719115765000_1.2.e100021.98","doi-asserted-by":"crossref","first-page":"105150","DOI":"10.1016\/j.jcv.2022.105150","article-title":"Performance of the Cobas\u00ae HBV RNA automated investigational assay for the detection and Quantification of circulating HBV RNA in chronic HBV patients","volume":"150\u2013151","author":"Scholt\u00e8s","year":"2022","journal-title":"J Clin Virol"},{"key":"2025081719115765000_1.2.e100021.99","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1002\/hep.32018","article-title":"Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America","volume":"74","author":"Ghany","year":"2021","journal-title":"Hepatology"},{"key":"2025081719115765000_1.2.e100021.100","doi-asserted-by":"crossref","unstructured":"Testoni B , Scholtes C , Plissonnier ML . n.d. Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B. Gut doi:10.1136\/gutjnl-2023-330644","DOI":"10.1136\/gutjnl-2023-330644"}],"container-title":["eGastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/egastro-2023-100021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T02:17:12Z","timestamp":1755483432000},"score":1,"resource":{"primary":{"URL":"http:\/\/egastroenterology.bmj.com\/lookup\/doi\/10.1136\/egastro-2023-100021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":100,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,10,24]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/egastro-2023-100021"],"URL":"https:\/\/doi.org\/10.1136\/egastro-2023-100021","relation":{},"ISSN":["2766-0125","2976-7296"],"issn-type":[{"value":"2766-0125","type":"print"},{"value":"2976-7296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}